Redeye decreases its fair value range for aXichem after reviewing the case and making significant changes to our financial estimates to apply a more realistic outlook for the coming years. Despite our lowered base case of SEK24 (57), we emphasize +68% upside from current levels and see aXichem’s most important milestone (regulatory approval) on the horizon. We thus believe sales should finally ignite shortly afterward.